Isaac M
Psychopharmacology Evaluation Unit, University Hospital, Lewisham, London, UK.
Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S101-6. doi: 10.1016/s0924-977x(99)00028-0.
During the past decade the selective serotonin reuptake inhibitors (SSRIs) have become established as the treatment of choice for depression. As newer antidepressants become available on the market, it is important to reappraise the position of the SSRIs in the management of depression. This review will address the question: where are we going with the SSRIs? The continued establishment of the SSRIs as first-line treatment for depression will be discussed, focusing on the more rapid onset of antidepressant efficacy seen with pindolol augmentation and the use of SSRIs for treatment of depression in patients with physical illnesses, particularly ischaemic heart disease. The SSRIs have well-documented efficacy in panic disorder and obsessive-compulsive disorder, and paroxetine has recently been licensed for social anxiety disorder/social phobia in some countries. Results will be presented from studies with the SSRIs in new therapeutic areas, including post-traumatic stress disorder and generalized anxiety disorder.
在过去十年中，选择性5-羟色胺再摄取抑制剂（SSRI）已成为治疗抑郁症的首选药物。随着市场上出现更新的抗抑郁药，重新评估SSRI在抑郁症治疗中的地位很重要。本综述将探讨这个问题：我们对SSRI的应用将走向何方？将讨论SSRI继续作为抑郁症一线治疗药物的情况，重点关注吲哚洛尔增效时抗抑郁疗效起效更快的情况，以及SSRI在躯体疾病患者，尤其是缺血性心脏病患者中治疗抑郁症的应用。SSRI在惊恐障碍和强迫症方面的疗效已得到充分证明，并且在一些国家，帕罗西汀最近已被批准用于社交焦虑障碍/社交恐惧症。还将介绍SSRI在新治疗领域（包括创伤后应激障碍和广泛性焦虑障碍）的研究结果。
